Institutional investors purchased a net $2.4 million shares of HALO during the quarter ended December 2014. This may signal that the smart money is gaining interest in this company as the 60.74% of shares outstanding that institutional investors hold is actually below the Biotechnology industry average.
Mutual fund holders
Largest Quarterly Institutional Transactions
Latest Institutional Activity
TFS CAPITAL LLC Bought 148.2 Thousand shares of Halozyme Therapeutics Inc